Travere Therapeutics prices $125M public offering of 7.8M shares at $16.00/share

Travere Therapeutics, Inc.

Priced 7,812,500 shares at $16.00 per share; gross proceeds of $125.0M.
Net proceeds expected ~$117.0M after underwriting discounts and expenses.
Underwriters have 30-day option to purchase up to 1,171,875 additional shares.
Closing expected November 12, 2024; Jefferies and Leerink Partners are joint book-runners.
Proceeds for general corporate purposes including commercialization and R&D.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.